Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx's KRAS Kit Approved by Chinese SFDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chinese molecular diagnostics firm Amoy Diagnostics today announced the Chinese State Food and Drug Administration has approved its KRAS mutation detection kit.

The Xiamen-based firm can now market its KRAS test for clinical use in China. In a statement, AmoyDx said the KRAS kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

The test "is a new tool for physicians and other healthcare providers to help them make more informed decisions on how best to combat their patients' cancers," David Whyte, executive vice president of global operations for AmoyDx, said in a statement.

The assay is based on the company's ADx-ARMS technology, which uses a two-step process to detect mutations in the KRAS gene. The method has been validated on several PCR platforms including the Roche Light Cycler 480 I and Light Cycler 480 II; Stratagene MX 3000P and 3005P; Applied Biosystems StepOne Plus 7300 and 7500; and Bio-Rad IQ5 and CFX96.

AmoyDx has also developed and validated test kits for EGFR and BRAF mutations based on the ADx-ARMS technology. It said that it anticipates SFDA approvals for the tests soon. It has applied for the CE Mark for its KRAS, EGFR, and BRAF assays.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.